Shanghai Unicell Biopharma

Unicell Biopharma is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of next-generation universal 'off-the-shelf' CAR-T cell therapies. The company leverages its proprietary C-Trade platform to produce allogeneic cell products derived from healthy donors or induced pluripotent stem cells (iPSCs), aiming to overcome the high costs and manufacturing complexities of traditional autologous treatments. Its lead candidate, UC101, is an allogeneic CAR-T therapy targeting BCMA for the treatment of relapsed or refractory multiple myeloma. Unicell is also expanding its pipeline into autoimmune diseases and other hematological malignancies. The company is supported by prominent venture capital investors and maintains state-of-the-art R&D and GMP manufacturing facilities in Shanghai.